BioInvent International Investor Relations Material
BioInvent International AB engages in the discovery, research, and development of immuno-modulatory antibodies for the treatment of cancer. The company develops products based on its proprietary F.I.R.S.T platform for antibody generation, which generates fully human antibodies. Its products under development comprise BI-1206 and BI-1207 for B cell malignancies; and BI-1701 for non-small cell lung cancer and head and neck cancer, as well as various other preclinical product candidates. The company was formerly known as BioInvent International AB changing its name to BioInvent International AB
Upcoming events for
Q2 20222022-08-25
Latest company events
Ticker symbol
BINV
Country
Sweden
Investor Relations Page
Dig deeper into the BioInvent International fundamentals on Quartr.
- Skip straight to the Q&A session
- Receive notifications about new events
- Connect the financial calender on your phone
- Figure out why the stock is up or down
- Read the transcripts or scroll the deck
- Access earnings or press releases
